We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04540900
Previous Study | Return to List | Next Study

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04540900
Recruitment Status : Recruiting
First Posted : September 7, 2020
Last Update Posted : August 16, 2021
Sponsor:
Information provided by (Responsible Party):
Krystal Biotech, Inc.

Brief Summary:
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Condition or disease Intervention/treatment Phase
Skin Roughness Wrinkle Fine Lines Skin Thickness Biological: KB301 Other: Placebo Phase 1

Detailed Description:
Up to thirty-seven (37) subjects divided into two (2) cohorts are planned for this Phase I study. Subjects enrolled in Cohort I will present a region of healthy buttock skin as a non-facial target area to receive two (2) injectable doses of KB301 (low or high). Cohort Ia will also present two regions of healthy buttock skin as a non-facial target area to receive two (2) injectable doses of KB301 (low or high) as well as a placebo injection. The objective of this cohort is to evaluate COL3A1 transgene expression (as measured by qRT-PCR of skin biopsies) and determine the optimal dose. Subjects enrolled in Cohort II will present with bilaterally symmetrical regions of moderate to severe fine lines and skin roughness as the target areas; these areas will be randomly assigned to receive either KB301 or a placebo to determine the extent of skin improvement in the KB301 arm. Throughout the study participants will complete questionnaires, have images captured of the target areas, undergo physical examinations, and have safety labs monitored.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
Actual Study Start Date : October 7, 2020
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Collagen

Arm Intervention/treatment
Active Comparator: KB301
non-integrating HSV-1 vector expressing human type III collagen injection
Biological: KB301
non-integrating HSV-1 vector expressing human type III collagen injection

Placebo Comparator: Placebo
sterile isotonic saline injection
Other: Placebo
sterile isotonic saline injection




Primary Outcome Measures :
  1. Assessment of the safety profile of KB301 by recording adverse events. [ Time Frame: 12 months ]
    The primary outcome will look at the safety of KB301 through the collection and quantification of adverse events. The Investigator will collect a description of the adverse event, time of onset, time of resolution, assess severity, and causal relationship to KB301.


Secondary Outcome Measures :
  1. Evaluation of COL3A1 transgene expression 2-days post-dose. [ Time Frame: 12 months ]
    The secondary outcome measure in Cohort 1 will compare a KB301 injection site biopsy, to an area of untreated healthy buttock skin biopsy (at least 6 cm away from the sites of KB301 injection), via qRT-PCR analysis.

  2. Assessment of skin roughness as compared to baseline, using the Skin Roughness Scale (SRS). [ Time Frame: 70 Days ]
    The secondary outcome measure in Cohort 2 will look at the mean change in the assessment of skin roughness as compared to baseline, using the Skin Roughness Scale (SRS). The SRS ranges from no fine lines (0) to extreme fine lines (4). A third-party independent blinded evaluator will perform the evaluations.

  3. Assessment of fine line improvement as compared to baseline, using the Fine Lines Scale (FLS). [ Time Frame: 70 Days ]
    The secondary outcome measure in Cohort 2, will look at the mean change in the assessment of fine lines as compared to baseline, using the Fine Lines Scale (FLS). The FLS ranges from no texture (0) to diffuse texture (4). A third-party independent blinded evaluator will perform the evaluations.

  4. Subject assessment of aesthetic improvement over baseline, using the Subject Satisfaction Scale (SSS). [ Time Frame: 70 Days ]
    The secondary outcome measure in Cohort 2, will look at the mean change in Subject's Satisfaction with the treatment per target area, as compared to baseline, using the Subject Satisfaction Scale (SSS), which is scored on a scale from 0 - 4, with 0 indicating not satisfied and 4 indicating excellent.

  5. Assessment of skin fold thickness in Cohort 2. [ Time Frame: 70 Days ]
    The secondary outcome measure in Cohort 2, will look at the mean change in skinfold thickness of the non-facial target areas, using a caliper to measure, as compared to baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female in good general health, as determined by the Investigator, aged ≥18 and ≤75 at the time of consent.
  2. Regions of suitable skin to be selected as Target Area(s), as determined by a physical examination conducted by the Investigator during the initial visit:

    1. Cohort 1 - single region of healthy buttock skin;
    2. Cohort 1a - bilaterally symmetric regions of healthy buttock skin at least 6 cm apart
    3. Cohort 2 - bilaterally symmetric regions of moderate to severe fine lines and skin roughness (score of 2 or 3), as determined by Investigator using the 5-point FLS and SRS on the cheeks above and below the zygomatic arch
  3. A Fitzpatrick skin phototype score of I-IV.
  4. A negative pregnancy test at the Study Day 0 Visit for subjects of child-bearing potential.
  5. Signed and dated informed consent and willingness to attend all study visits and complete all procedures required by this protocol.

Exclusion Criteria:

  1. Any transient or chronic skin condition, disorder, or infection within 20 cm of the Target Areas at Day 0 that, in the opinion of the Investigator, may confound study results.
  2. History of laser treatment or chemical peels to the Target Areas within six months of the Study Day 0 Visit.
  3. History of surgical procedures to Target Areas, including removal of benign or malignant skin cancers that, in the opinion of the Investigator, may confound study results.
  4. Administration of a cosmetic and/or clinical research investigational agent, excluding KB301, at the location of the Target Areas within 3 months of the Study Day 0 Visit, that, in the opinion of the Investigator, may confound study results.
  5. Any condition (including a history or current evidence of substance abuse or dependence) that, in the Investigator's opinion, would impact subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of the Investigational Product.
  6. An active oral herpes infection at the Screening Visit or Study Day 0 Visit.
  7. Women who are pregnant or nursing.
  8. Subject who is unwilling to comply with contraception requirements per protocol.
  9. A history of anaphylaxis or allergic reactions to any of the constituents of the product and/or local anesthetics.
  10. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol, in the opinion of the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04540900


Contacts
Layout table for location contacts
Contact: Brittani Agostini 412-586-5830 bagostini@krystalbio.com

Locations
Layout table for location information
United States, California
Steve Yoelin, MD Medical Associates, Inc. Recruiting
Newport Beach, California, United States, 92663
Contact: Nubia Fernandez       nubiaf19@gmail.com   
Principal Investigator: Steve Yoelin, MD         
Mission Dermatology Recruiting
Rancho Santa Margarita, California, United States, 92688
Contact: Margarida Pinto       gpinto.missionderm@gmail.com   
Principal Investigator: Shireen V Guide, MD         
United States, Florida
Skin and Cancer Associates, LLP. D/B/A Center for Clinical and Cosmetic Research Active, not recruiting
Aventura, Florida, United States, 33180
Sponsors and Collaborators
Krystal Biotech, Inc.
Layout table for additonal information
Responsible Party: Krystal Biotech, Inc.
ClinicalTrials.gov Identifier: NCT04540900    
Other Study ID Numbers: PEARL-1
First Posted: September 7, 2020    Key Record Dates
Last Update Posted: August 16, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Krystal Biotech, Inc.:
KB301
Wrinkles
Krystal Biotech
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Behavioral Symptoms